

Index

| Aalbersberg, Bill, 263 | freedom to operate analysis, 228, 235 |
|--|--|
| Abbott, 314 | geographical scope of IP rights, limits on, |
| ABCD model of transfer of IP rights, 85 | 232 |
| downstream transfers, 266 | government use, 236–237 |
| open access and, 181, 182 | innovation cycle and (See Innovation cycle) |
| procurement practices and, 153–154 | legal defects in IP rights, seeking, 234–235 |
| Academic freedom, 298 | license, by, 231 |
| Acambis, 332 | litigation and, 237 |
| Access and benefit sharing agreements, 304 (See | music, 231 |
| Biodiersity) | negotiation and, 237 |
| "Accessible domain" (See Public Domain) | open access (See Open access) |
| broadly accessible information, 49 | overview, 238 |
| concerns, 51 | pharmaceuticals, 231–232 |
| enlargement of, 57 | plants, 231 |
| fully accessible information with no IP rights, | purchase, by, 231 |
| 48–49 | respecting IP rights, 228 |
| infringement and, 91 | screening of innovations, 227–228 |
| limited purposes, information accessible for, | software, 231 |
| 49–50 | third-party IP rights, 237 |
| mapping of, 48 | weakness in scope of IP rights, seeking, 232 |
| non-accessible information, 50 | Acetaminophen, 124 |
| relative strength of IP rights, significance of, | Acquisition of IP rights (See Copyrights, Patents, |
| 50–51 | Trademarks, and Trade Secrets) |
| spectrum of information contained in, 50 | ABCD model and, 266 |
| tree metaphor and, 64–65 | balancing of rights, 266 |
| Access to innovation | creation, via, 265–266 |
| access not readily available, when, 231-238 | downstream transfers, 266 |
| access readily available, when, 229-231 | overview, 265 |
| alternatives, seeking, 232–234 | partnering relationships, 266 |
| balancing with exclusion (See Balancing | transfer agreement, via, 266 |
| access and exclusion) | Adobe Acrobat Reader, 172, 231 |
| bargaining chips, 234 | Aeschylus, 28 |
| blocking rights, 237 | African Intellectual Property Organization |
| challenging IP rights, 237–238 | (OAPI), 33 |
| "chilling effect" of IP rights, 228–229 | African Regional Intellectual Property |
| compulsory licenses, 236 | Organization (ARIPO), 33, 320 |
| decision trees, use of, 229 | Africa Rice Center (WARDA), 107, 108 |
| "designing around" patents, 234 | Agence France Presse, 136 |
| duration of IP rights, limits on, 232 | Agreement on Trade-Related Aspects of |
| fair use (See Fair use) | Intellectual Property Rights. See TRIPS |
| first sale doctrine and, 229–231 | Agreement |
| | |

390



| Agriculture and developing countries, 55, | Assignment of IP rights |
|---|--|
| 107–108 | contracts, 269 |
| AIDS medicines | employment contracts, in, 268 |
| Brazil, in, 128 | joint ventures, in, 268 |
| conversion to different type of IP, 79 public domain and, 47 | licensing distinguished, 273–274 liens, 270 |
| - | |
| unnamed co-inventor and AZT, 178 | mergers, in, 268–269 |
| Alcatel-Lucent, 315 | noneconomic terms, 279 |
| "Aleppo Citadel" strategy, 170 Alexander the Great, 13 | recordation of, 269, 270 |
| · · · · · · · · · · · · · · · · · · · | security interests, 270 |
| Allied Domecq, 317 | Association of University Technology Managers, |
| Alternate dispute resolution, comparative law | 34, 218, 298 |
| re, 313 | Atari, 151–152 |
| Amazon.com, 140, 306 | AT&T, 313 |
| American Academy for the Advancement of | Auctions |
| Science, 298 | assignment of IP rights by, 269 |
| American Arbitration Association, 313 | IP assets, auctioning of, 219 |
| American Type Culture Collection, 292 | Australia |
| Andean Community (ANCOM), 320 | standards for obtaining patents, 310 |
| Andean Pact, 33 | volume of patents, 311 |
| Annan, Kofi, 301 | Authorship, concept of, 73, 151 |
| Ansari X Prize, 58 | Avian flu, 313, 330–331 |
| "Anti-invent around" strategy, 176 | Awards as alternative to IP rights, 58–59, 343 |
| Antitrust law, 41, 283–284 | |
| Apotex, 329 | Bailment, 272 |
| Apple Computers | Balanchine, George, 301 |
| access to software, 231 | Balancing access and exclusion |
| formation of, 117, 152 | biodiversity and, 52 |
| innovation communities in, 98, | copyrights and, 45, 51 |
| 101 | freedom and, 343 |
| joint ventures, 158 | genetic resources and, 52 |
| mission statement, 139 | goals of IP management, as, 163–164 |
| screening of innovations, 228 | importance of, 45, 51 |
| trademarks, 75, 76 | overview, 59 |
| Applera, 118 | patents and, 45, 51 |
| Apple Records, 89 | real property analogy, 45 |
| Arbitration, comparative law re, 313 | tension between access and exclusion, 43-44 |
| Archon X Prize for Genomics, 59 | trademarks and, 45, 52 |
| Arrow, Alexander, 219 | trade secrets and, 45, 52 |
| Arvigo, Rosita, 108, 109 | Bargaining chip strategy, 170–171 |
| Aspartame, 80, 175 | Barr Laboratories, 178 |
| Aspirin, 19, 49 | "Barter" agreements, 271 |
| Assessment of IP | Barton, John, 54 |
| external environment evaluation (See | Bavarian Nordic, 332 |
| External environment evaluation) | Bayer, 49, 329 |
| failure to undertake, problems arising from, | Bayh, Birch, 34 |
| 184 | Bayh-Dole Act, 33-34 |
| internal asset evaluation (See Internal asset | enactment of, 34 |
| evaluation) | government licenses to patents under, 272 |
| inward versus outward assessment, 184 | IARCs, applicability of model to, 204 |
| overview, 184, 205–206 | Indian law, similarity of, 318 |
| regular assessment importance of 184 | ownership of IP rights under 270 |



| Bayh-Dole Act (cont.) | IP management strategies and, 168 |
|--|---|
| partnership model under, 33–34 | licensing of patents, 277–278 |
| patent applications under, 203 | litigation re, 238, 261, 315 |
| required licensing under, 158 | patent protection, importance of, 293 |
| similar acts in other nations, 34 | patent "trolls" and, 172 |
| universities, impact on, 34, 103, 297 | valuation of IP assets and, 216–217, 222 |
| Bell, Alexander Graham, 14 | Black-Scholes option pricing formula, |
| Benchmarking, 144 | 219–220 |
| Benedict XVI, Pope, 106, 301 | "Blanket" strategy, 173 |
| Benefit sharing agreements, 271 | Blocking rights |
| Berne Convention | bargaining chip, as, 237 |
| copyright protection under, 244 | biotechnology, in, 91 |
| historical background, 32 | enforcement tool, as, 254 |
| moral rights under, 38, 275 | infringement and, 91 |
| Bill and Melinda Gates Foundation, 110, 299, | pharmaceuticals, in, 91 |
| 330 | Bolar provisions, 314 |
| Biodiversity (See Convention on Biological | Bowie, David, 214, 296, 324 |
| Diversity) | Boyer, Herbert, 117 |
| agreements, 271 | Branding, 179–180 |
| balancing access and exclusion and, 52 | Brazil |
| biopiracy and, 311, 317, 319, 337 | AIDS medicines in, 128 |
| Biological materials | compulsory licenses in, 314 |
| access and benefit sharing agreements, 304 | negotiation, role of, 312 |
| balancing access and exclusion in, 52 | patents, 311 |
| copyrights in, 292, 304 | piracy in, 313 |
| IP rights in, 77 | examples of IP law, 317 |
| material transfer agreements (MTAs), 272, 304 | "BRIC" countries, 316–317 |
| patents in, 79, 292, 303-304 | Bristol-Myers Squibb, 209, 329 |
| plants (See Plants) | British Museum, 45 |
| quasi-IP rights, 304 | Brock, Thomas, 18 |
| strategic IP management, 291–292 | Broder, Sam, 178 |
| trademarks in, 292–293, 304 | Budapest Treaty on the International |
| trade secrets in, 79, 292, 302 | Recognition of the Deposit of |
| Biotechnology | Microorganisms for the Purposes of |
| access, importance of, 338 | Patent Protection, 303 |
| blocking rights in, 91 | "Burning stick" strategy, 166–167 |
| criticism of, 337 | |
| developing countries and, 55 | California, University of, 98, 102, 118, 203, |
| genetic sequences (See Genetic sequences) | 298 |
| human rights considerations, 337 | Cambridge University, 102 |
| innovators, position of, 336, 337 | Canada |
| IP, role of, 337–338 | compulsory licenses in, 314 |
| moral considerations, 338 | patents, volume of, 311 |
| open access and, 336 | Canon, 293 |
| patent disclosure requirements, 336–337 | Capetown, University of, 102 |
| political considerations, 336 | Cash value model for valuation. See |
| public interest advocates, position of, 336, 337 | Income-based valuation |
| Bioversity International, 103 | CBD. See Convention on Biological |
| Bird flu (See Avian flu) | Diversity |
| Blackberry | Celebrex, 328 |
| customer interest in, 47, 118–119 | Celera Genomics, 69, 109–110, 118 |
| geographic scope of patents re, 232 | Challenging IP rights of others, 237–238 |



| Charitable donations, sunk cost-based | Communities of innovation |
|---|---|
| valuation in, 213 | common threads, 98 |
| Chevron, 174 | corporations, 101–102 |
| Chiang Mai University, 102 | developing countries (See Developing |
| Chiefs. See Innovation chiefs | countries) |
| "Chilling effect" of IP rights, 228–229 | differences between, 98 |
| China | global innovation initiatives, 111–112 |
| Administration for Industry and Commerce, | individuals (See Individuals and innovation) |
| 318 | Internet as global innovation initiative, |
| Beijing Olympics, 205 | 111–112 |
| examples of IP law, 318–319 | multinational research consortia (See |
| negotiation, role of, 312 | Multinational research consortia) |
| patents, volume of, 311 | nonprofit organizations (See Nonprofit |
| piracy in, 313 | organizations) |
| Public Service Bureau, 318 | open innovation communities (See Open |
| trademarks in, 311 | innovation communities) |
| Choice and innovation, 342-343 | overview, 97–98, 114 |
| Christenson, Clayton, 101, 125, 128 | political parties, 104–105 |
| Churches. See Religious organizations | regional innovation communities, 106–107 |
| CIPIH, report on pharmaceuticals and | religious organizations (See Religious |
| developing countries, 55–56 | organizations) |
| CIPR. See Commission on Intellectual Property | small businesses, 100–101 |
| Rights | small groups (See Small groups and |
| Ciprofloxacin, 329 | innovation) |
| Claritin, 175, 329 | types of, 98 |
| Clean Air Act, 20 | universities, 102–103 |
| Clean Water Act, 20 | Comparative law. See also specific country |
| Clickwrap licenses, 271 | alternate dispute resolution, 313 |
| Cluster theory of competition, 125-126 | arbitration, 313 |
| Coca-Cola | compulsory licenses, 314 |
| exclusivity and, 254 | copyrights, standards for obtaining, 312 |
| IP thicket strategy, 168–169 | counterfeiting, 313 |
| trademarks, 74, 143, 251, 271 | country to country variations, 309 |
| trade secrets, 67, 179, 244, 259, 267, 273, 290 | criminal offenses, 314 |
| Cohen, Stanley, 117 | developing countries, in, 319 |
| Co-inventors, 178 | enforcement of IP rights, 312-313, 314-315 |
| Collaborators. See also Joint ownership | language requirements, 310 |
| infringement and, 92 | mediation, 313 |
| Colleges. See Universities | negotiating, 312 |
| Collins, Frances, 14, 110 | overview, 321 |
| Comedy, copyrights and, 301 | patents, 310–311 |
| Commission on Intellectual Property Rights, | patterns of innovation, 309 |
| Innovation and Public Health (CIPIH), | piracy, 313 |
| report on pharmaceuticals and | protection of innovation, 309 |
| developing countries, 55–56 | strategic IP management, 308–309 |
| Commission on Intellectual Property Rights | trademarks, standards for obtaining, 311–312 |
| (CIPR) | Compulsory licenses |
| balancing access and exclusion, 51 | bargaining chip, as, 236 |
| developing countries, report re, 53–55 | comparative law re, 314 |
| "one size fits all" approach, rejection of, | generic drugs, 330 |
| 54–55 | homeland security technology, 332 |
| overview 53–54 | operation of law transfer of IP rights by 272 |



394 Index

Computer programs. See Software difficulty of, 73 Confidentiality agreements overview, 72-73 employment contracts, in, 150 prerequisites, 71-72 entertainment industry, in, 295 entertainment industry, in, 295-296 internal asset evaluation and, 196 external environment evaluation (See software and, 305-306 External environment evaluation) trade secret theft and, 259 fair use of, 235 infringement, damages, 222 Consideration, 264–265, 269 Consultative Group on International interactions with other types of IP, 78-79 Agricultural Research (CGIAR), 203-204 internal asset evaluation re (See Internal asset Consumer products and services evaluation) life sciences, in, 292 copyrights in, 294 labeling, 293-294 maintenance, 250 strategic IP management, 293 music, in, 296 trademarks in, 294 non-strategy model of IP management, effect trade secrets in, 294-295 of, 133 Contracts overview, 71, 83 ABCD model and, 85 ownership of, 267 assignment of IP rights, 269 piracy of copyrighted material, 73 enforcement of IP rights, not necessary for, 85 portfolio management, 250-251 transfer of IP rights, 87 protection of innovation Convention on Biological Diversity (CBD) high level of investment, 245 adoption of, 25 low level of investment, 245 balancing access and exclusion, 52 notice, importance of, 244-245 bargaining under, 209 public domain environmental technology and, 334, 335 dedication to, 250-251 historical background, 33 entry of copyrighted material into, 72 involvement of new groups under, 56 public speeches and, 301 legal rights to biological materials under, 77 registration, 250 licensing of genetic resources under, 272 religious organizations and, 106 national sovereign rights under, 304 rights of owners, 72-73 "self-help," 73 traditional knowledge, protection of, 52, 78, 336, 337 software, in, 293, 306 Conversion to different type of IP, 79–81, 175 strategic IP management, copyright-specific "Copyleft" licenses, 42, 112, 276 (See also Open strategies, 181 sunk cost-based valuation, 212 Copyright Act, 38, 301 symphony orchestras and, 300-301 Copyrights, 71-73 table, 72 authorship, concept of, 73 telecommunications, in, 293 theater and, 299-300 balancing access and exclusion in, 45, 51 trade secrets, relationship with, 69 Berne Convention, protection under, 244 biological materials, in, 292, 304 transfer of IP rights (See Transfer of IP rights) "chilling effect" of IP rights and, 229 TRIPS Agreement, protection under, 244 comedy and, 301 United Nations using, 202 comparative law re standards for obtaining, universities and, 299 visionary model of IP management, effect of, consumer products and services, in, 294 135-136 conversion to different type of IP, 79-81 WHO using, 202 dance and, 301 WIPO using, 202-203 electromechanical equipment, in, 305 Corporations electronics, in, 293 innovation and, 101-102 enforcement of, 259-260 internal assets valuation in, 188, 189



| management of innovation in, 126–127 | Dali, Salvador, 18 |
|--|---|
| ownership of IP rights distinguished from | Dance, copyrights and, 301 |
| ownership of corporations, 268 | Databases, 77, 79 |
| strategic IP management, 290 | Davila, Tony, 124, 125, 128 |
| valuation of IP assets in, 208 | da Vinci, Leonardo, 123 |
| Cost-based valuation, 211–214 | DC Comics, 79, 297 |
| replacement cost, 213–214 | DDT, 20 |
| sunk cost | Dealing in IP rights. See Transfer of IP rights |
| advantages, 213 | Definitions of IP, 22–23 |
| charitable donations, 213 | accounting definition, 23 |
| copyrights, 212 | dictionary definition, 22–23 |
| disadvantages, 213 | legal definition, 23 |
| illustrations, 212–213 | management definition, 23 |
| overview, 211–212 | scholarly definition, 23 |
| patents, 212 | Dell Computers, 171, 280 |
| trademarks, 212 | Delta Faucet Company, 175 |
| trade secrets, 212 | "Designing around" patents, 234 |
| Cost management, 159–161 | Design patents, 71 |
| counsel, hiring of, 160 | Developing countries. See also specific country |
| deciding what assets to protect, 159 | agriculture and, 55, 107–108 |
| human resource management, importance | biotechnology and, 55 |
| of, 159–160 | CIPR report, 53–55 |
| leadership, importance of, 160-161 | external environment evaluation, 203 |
| organizational management, importance of, | innovation in, 107–109 |
| 160 | access to IP professionals, lack of, 109 |
| variation in costs, 159 | authoritarian governments, problem of, |
| Counterfeiting, comparative law re, 313 | 108 |
| Creative Commons, 172, 182, 276 | collaboration with other organizations, 109 |
| "Creative construction," 57–58, | importance of, 109 |
| 124 | obstacles to, 108 |
| Creative destruction | overview, 107 |
| freedom and, 344 | poverty, problem of, 108 |
| management of innovation, applied to, 122, | traditional knowledge and, 108–109 |
| 125 | IP law in, 319 |
| Schumpeter on, 11–12, 19 | patterns of innovation in, 309 |
| Crick, Francis, 303 | pharmaceuticals and, 55 |
| Criminal offenses, 314, 317, 319 | CIPIH report, 55–56 |
| Criticism of IP, 40–43 | tension re IP system in, 53–56 |
| competition, promotion of, 42 | enforcement issues, 53 |
| cost of obtaining and maintaining, 42 | Eurocentric nature of IP system, 53 |
| cost of technology, increasing, 41 | overview, 53 |
| inappropriate concentration of industry, 42 | trademarks and, 108 |
| legal and regulatory framework, requirement | TRIPS Agreement, lack of full implementation |
| of, 42 | of, 309 |
| monopolies, creation of, 41 | Diamond, Jared, 14, 15 |
| moral objections, 43 | Digital Maoism, 43 |
| overview, 36–37, 40, 59 | Digital Millennium Copyright Act of 1998, 297 |
| procurement practices, overcoming through, | Dinwoodie, Graeme B., 48 |
| 155–156 | Doha Declaration, 314 |
| public domain, keeping innovation out of, 40 | Domain names, 76, 112, 313 |
| Cross-license agreements, 271 | "Do-nothing" organizations, converting, 165 |
| Customers and infringement, 93–94 | Dove-Edwin, Beatrice, 320 |



396 Index

Dreamworks, 324 End user license agreements (EULAs), 271, Dreyfuss, Rochelle Cooper, 48 Drucker, Peter Endy, Drew, 304 Enforcement of IP rights corporations, on management of innovation in, 127 blocking rights, 254 "creative construction" concept and, 124 comparative law re, 312-313, 314-315 creative destruction concept and, 122 confronting infringers, 159 government planning, on role of, 124 control of rights and, 254 innovation communities, on, 101 copyrights, 259-260 IP management, on, 124 difficulty of, 73 management of innovation, on, 122-124 overview, 72-73 new and old ventures, on separating, 124 prerequisites, 71-72 sources of innovation, on, 122, 123, 128 costs, 254 universities, on, 102 exchange of rights for value, 254 Drugs. See Pharmaceuticals external environment evaluation and, Due diligence in external environment 201-202 evaluation, 198, 199-200 historical background, 253 Duration of IP rights, limits on, 232 importance of, 253-254 Dynamic conceptual framework of IP rights, 63, licenses, 281 96 litigation and, 159, 254 Dynamic innovation theory, 41 monitoring, 158-159 notice of rights, importance of, 158 East Coast Fever vaccine project, 109 other rights, 261 Eastman Kodak, 75, 119, 208, 238, 251, 261, 315 overview, 158, 162, 255, 262 eBay, 140 patents, 260-261 Edison, Thomas, 14, 100, 124 "sleeping on rights," 159 strategic IP management, in, 158-159 Egypt criminal offenses in, 314 tension regarding, 53 overview of IP in, 26-28 trademarks, 75, 260 Eisenberg, Rebecca, 44 trade secrets, 68, 257-259 Electromechanical equipment Enforcement triage copyrights in, 305 decision-making, 257 integrated circuits, 305 infringement analysis licensing of IP rights, 305 infringement, 257 patents in, 305 validity, 257 strategic IP management, 304-305 overview, 255 trademarks in, 305 threshold questions, 255-257 Electronics English law, IP under, 25, 29-30 Entertainment industry copyrights in, 293 patents in, 293 confidentiality agreements, 295 strategic IP management, 293 copyrights in, 295-296 trademarks in, 293 music (See Music) trade secrets in, 293 patents in, 295 Emory University, 189, 215, 221, 324 public performances (See Public Employee rights, 77 performances) Employment (See also Personnel practices) strategic IP management, 295 trademarks in, 297 internal asset evaluation, issues in (See trade secrets in, 295 Internal asset evaluation) key employees new job, 51 Entertainment licenses, 270 Environmental technology infringement and, 92 personnel practices (See Personnel practices) benefits of, 334 Employment contracts, 150, 196, 268 complexity of, 333, 335-336



Index 397

environmental impact, consideration of, exclusivity, 200-201 333-334 freedom to operate, 201 IP. role of, 334-335 trade secrets market forces, promotion via, 334 assets, 201 overview, 333 exclusivity, 201 patents in, 335 freedom to operate, 201 technology-forcing regulations, 334 widespread availability of information, technology transfer, role of, 335 198-199 trademarks in, 335 trade secrets in, 335 Fairness and innovation, 344 US, environmental regulation in, 333 Fair use, 235-236 copyrights, of, 235 Eolas, 315 Established royalty rates, use in valuation, 220 overview, 235 EU Database Directive, 77 patents, of, 235-236 European Commission, 315 trademarks, of, 235 European Patent Convention, 33 trade secrets, of, 236 European Patent Office (EPO), 310, 311, 315 "Fence" strategy, 173 European Union (EU) Fictional characters, 79, 297 community trademarks in, 245, 316 Field of use, 279-280 summary of IP law, 315-316 File reproduction technology, 56, 296-297 Evaluation of IP "First one's free" strategy, 172 external environment evaluation (See First sale doctrine, 229-231 External environment evaluation) 5% rule in valuation, 220-221 internal asset evaluation (See Internal asset "Flood" strategy, 173 evaluation) Flow of IP rights. See Transfer of IP rights Exclusion from innovation Food and Agriculture Organization, 103 balancing with access (See Balancing access Food and Drug Administration (FDA), 80, 215, and exclusion) 216 exclusivity, 279, 343 Ford Motor Company, 174 External environment evaluation Forest analogy, 81-82 copyrights Forest strategy, 169-170 assets, 201 Franchises exclusivity, 201 licenses, 271 freedom to operate, 201 partnering practices and, 157-158 developing countries, 203 Freedom and innovation due diligence, 198, 199-200 balancing access and exclusion, 343 enforcement of IP rights and, 201-202 choice and, 342-343 failure to undertake, problems arising from, creative destruction, 344 199 exclusivity, effect of, 343 expansion of, 342 governmental agencies, 202-203 fairness and, 344 internal asset evaluation, relationship to, 187 issues to be addressed, 185 Lincoln on, 343-344 litigation, obtaining information in, 198 Freedom to operate analysis, 228, 235 negotiation, obtaining information in, 198 Friedman, Tom, 13 nonprofit organizations, 202-203 Gallo, Robert, 14 patents, 200 Gates, Bill, 100 assets, 200 G.D. Searle, 80, 175 exclusivity, 200 freedom to operate, 200 GenBank, 67, 182 sources of information, 198 Genentech, 98, 117 trademarks, 200 General Electric, 113 assets, 200 General Motors, 152, 259



398 Index

Generic drugs versus branded drugs Google balancing of interests, 326, 330, 331 copyrights and, 135-136 compulsory licenses, 330 extra value in product, 140 economic arguments, 326 internal IP assets, evaluation of, 188-189 examples of, 328-329 scanning of books by, 251 false dichotomy, 328 Gould, Gordon, 14, 99, 176 globalization of generic industry, 330 Governmental agencies incentives for generic companies, 328 evaluation "medicine here versus medicine elsewhere," copyrights, 202-203 329-330 overview, 202 "medicine now versus medicine later," patents, 203 326 trademarks, 203 overview, 325 trade secrets, 202 homeland security technology, access to, 332 patent expiration, impact of, 328 pharmaceutical "ecosystem" and, 326 license rights, 272 populist arguments, 326 strategic IP management, 297 public-private partnerships, 330 valuation of IP assets, 222-223 public research versus private research, Government use of innovations of others, 326-328 236-237 Genetic sequences Granting clauses, 279 open innovation communities and, 113 Grants as alternative to IP rights, 58-59, 343 patents, 79 Greece, IP in, 28 procurement practices and, 154-155 Guei, Robert, 108 trade secrets in, 302-303 Guinness, 244, 290 Geographical indications, 76-77 Gupta, Anil, 57, 98 Geographical scope of IP rights, limits on, 232 Haiti, summary of IP law, 319 Georgia-Pacific factors, 218-219 Hardin, Garrett, 44 Germany Harrison, George, 259-260 Blaue Engel program, 335 Hatch-Waxman Act, 284, 328 Glaxo Smith Kline, 329 Heller, Michael, 44 Glazier, Stephen, 173, 175 Hewlett-Packard, 293 Global challenges, 341 Historical background of IP, 22-35 Global Forum for Health Research, 42 Bayh-Dole Act (See Bayh-Dole Act) Global Fund to Fight AIDS, Tuberculosis and diversity of, 26 Malaria, 111 dynamic view of, 25-26 Global innovation initiatives, 111-112 early treaties, 32 GNU Free Documentation License, 276 Egypt, in, 26-28 Goals of IP management emergence of social institutions and, 26 ad hoc decisions, avoiding, 139 English law, 25, 29-30 balancing access and exclusion, 163-164 Greece, in, 28 communication of, 139-140 Industrial Revolution, during, 31-32 consistency of, 141 innovation, relationship with, 24 control, increasing, 140 Jewish law, 28 defining, 139-141 lack of public disclosure, impact of, 28 for-profit companies, relevance to, 164 Lincoln on, 28-29 list of general goals, 164 Middle Ages, during, 28 long-term versus short-term results, 140-141 modern treaties, 32-33 mission statements, 139 natural law concepts, 24 overview, 24, 26, 34-35 nonprofit organizations, relevance to, 164 social goals distinguished, 163 philosophical debate re, 32 Goodwill, 142 Rome, in, 28



| special nature of IP system, 24 | disadvantages, 215 |
|--|--|
| trademark concepts, 28 | discounted cash flow, calculation of, 214, 216 |
| US Constitution, 24–25 | illustrations, 214, 215–216 |
| Venetian Patent Decree of 1474 (See Venetian | net present value, calculation of, 214, 216 |
| Patent Decree of 1474) | overview, 214 |
| Hitachi, 293 | projected sales volume, importance of, 216 |
| Hitler, Adolf, dark side of innovation and, 20 | relief from royalty model, 217 |
| HIV medicines | time, importance of, 216 |
| Brazil, in, 128 | Indemnity, 281–283 |
| conversion to different type of IP, 79 | India |
| public domain and, 47 | Bayh-Dole Act, similarity of law to, 318 |
| unnamed co-inventors and, 178 | compulsory licenses in, 314 |
| Holding companies, 157 | examples of IP law, 317 |
| Homeland security technology | pharmaceutical industry in, 40 |
| balancing of interests, 332–333 | piracy in, 313 |
| compulsory licenses, 332 | Traditional Knowledge Digital Library, 318 |
| expedited patent process, 331–332 | TRIPS Agreement, laws adopted in |
| governmental agencies, access by, 332 | compliance with, 117 |
| innovation, role of, 331 | Indian Institute of Technology, 26 |
| IP management strategies, 331 | Indian National Innovation Foundation, 99 |
| trade secrets in, 332 | Individuals and small groups and innovation, |
| "Homesteading" strategy, 172–173 | 98–100 |
| Honda, 293 | Bangladesh, in, 99 |
| Honeybee Network, 57, 98 | disadvantages of, 99–100 |
| • | downplaying role of, 14 |
| Hu Jintao, 319 | 1 , 0 |
| Human genome, trade secrets and, 69 | India, in, 98–99 |
| Human Genome Project, 69, 109, 110 | overview, 98 |
| "Hurdle" strategy, 174 | successful models, 100 |
| Hybrid methods of valuation, 218–220 | US, in, 99 |
| Hypothetical royalty negotiations, valuation by, | Indonesia, piracy in, 313 |
| 218–219 | Industrial Revolution, IP during, 31–32 |
| IDM (| Infringement, 92–94 |
| IBM | "accessible domain" and, 91 |
| IP portfolio of, 41, 143 | blocking rights, 91 |
| open access and, 182 | collaborators and, 92 |
| open peer review, 113 | confronting infringers, 159, 167 |
| patents | copyrights, damages, 222 |
| cross-licensing of, 171 | customers and, 93–94 |
| licensing of, 136, 277 | infringing path, 93 |
| volume of, 118, 293 | internal activities, use of IP for, 92–93 |
| trademark protection, 293 | key employees and, 92 |
| ICICI, 324 | liability for, 93 |
| ICRISAT, 108 | non-infringing path, 93 |
| Igen, 208, 217, 222, 238 | organizational level, at, 92 |
| Imhotep, 13 | overlapping rights and, 91 |
| Implementation of strategic plan, 145–146, | overview, 95–96 |
| 226–227 | patents |
| Implied licenses, 271 | damages, 222 |
| Improvements, 281 | defenses, 70 |
| Income-based valuation | remedies, 70 |
| advantages, 214–215 | procurement practices, effect on, 155 |
| decision trees, use of, 215, 216 | trademarks, damages, 222 |



400 Index

Infringement (cont.) titles of, 115-116 trade secrets, damages, 222 types of, 115-116 two-way nature of, 92, 94 Innovation cycle, 15-19, 63, 81, 82, 98, 103 Innovation accessibility stage, 18-19 access to (See Access to innovation) circular model, 16 creative destruction and, 19 communities of (See Communities of innovation) creative work stage, 17-18 competition and, 14 diffusion stage, 18 complexity of, 15 dynamics, 46, 58, 59, 64, 94-95, 299, 325, 340 creative destruction and, 11-12 enforcement and, 254 developing countries, in (See Developing flow of IP rights and, 84, 263, 285 countries) forest analogy, 81-82 drawbacks of, 20-21 individuals and, 100, 344 difficulty in regulating, 21 innovation chief and, 116, 147 environmental problems, 20 linear model, 15-16 nanotechnology, 20-21 overview, 15 overview, 20 patents and, 71, 179 political problems, 20 public domain, effect on, 46 economic factors influencing, 15 trade secrets and, 80 freedom and (See Freedom and innovation) valuation and, 224 "heroic theory" of, 13-14 Innovation forest metaphor, 81–82 historical background, 12-13 Innovation teams, 119-122 homeland security technology, role in, 331 background of members, 119-120 individuals and (See Individuals and business experts, 120-121 innovation) creativity experts, 120 IP, relationship with, 12, 15, 24, 53, 94-95 globalization, impact of, 121-122 law, impact of, 14-15 legal experts, 120 management of (See Management of necessity of, 116 innovation) outsourcing of, 121 overview, 11, 21 overview, 128 personal versus social level, 15 senior management members, 121 structure of teams, 121 precautionary principle and, 20 protection of (See Protection of innovation) usefulness of, 119 reasons for, 13-15 Innovation tree metaphor, 64 securitization of IP rights, impact of, 325 country-to-country differences, 65-66 self-interest and, 13 new information and, 64-65 social demand for, 13 types of IP rights, 66 (See also specific topic) societal ability to adopt, 14 Innovation triage, 240-242 Innovation chiefs high level of investment, 240 imminent loss of rights, threat of, 242 corporate hierarchy, in, 115-116 low level of investment, 240-242 damage caused by, 118-119 effectiveness of, 118 no investment, 242 enabling of creativity, 117 overview, 240 human stories behind, 116-118 portfolio management, in, 248-249 innovation teams, necessity of, (See also timing considerations, 242 Innovation teams), 116 Institute for Genomics Research, the, 103, 109 leadership, importance of, 116-119 (See J. Craig Venter Institute) overview, 115, 128 Institute for One World Health, 299 power struggles involving, 118 Integrated circuits, 305 questions addressed by, 116 Intel, 278, 293, 305 "real world" dimension of, 116 Intellectual asset management (IAM), 126-127 reliance on, 117 Intellectual capital management (ICM), 126-127



Index 401

Intellectual Property Owners Organization, 293 overview, 189-190 Intellectual Ventures, 118, 136 sample, 375 (See Appendix C) Interactions between types of IP, 78-79 short questionnaires, 190 Interdisciplinary dynamic approach to IP, 12 scope of, 187-189 Intergovernmental Panel on Climate Change, tailoring of, 187-188 timing issues, 185-186 Internal activities, use of IP for, 92-93 trademarks, 194 Internal asset evaluation internal procedures, review of, 194 agreements, 197-198 nonregistered names, listing, 194 basic steps, 186-187 overview, 194 benefits of, 189 potential infringement, discovering, commercial enterprises, in, 188, 189 common IP-generating activities, 188 registered trademarks, listing, 194 copyrights, 194-195 trade secrets, 195-196 applied for, 194 continuing evaluation, 196 categories of works, listing, 194 disclosures of confidential information, internal procedures, review of, 195 identifying, 195-196 outsiders, works created by, 194-195 outsider information, use of, 196 software licensing issues, 195 overview, 195 deciding what to protect, 187 prioritizing confidential information, different methods, 186 difficulty of, 185-186 process audit approach, 195 employment issues, 196-197 universities, in, 189 confidentiality agreements, 196 Internal Revenue Service, 213 employment contracts, 196 International agricultural research centers noncompetition covenants, 196 (IARCs), 203-204 outsider information, use of, 196-197 International Association for the Study of external environment evaluation, Common Property, 52 relationship to, 187 International Center for Agricultural Research, issues to be addressed, 185 licenses, 197-198 International Chamber of Commerce, 313 International Livestock Research Institute, 103, listing registered IP rights, 186 nonprofit organizations, in, 188 109 International Trade Commission (ITC), 332 overlapping concerns, 189 patents, 192-193 International Treaty on Plant Genetic Resources coordinators, role of, 193 for Food and Agriculture counsel, role of, 192, 193 balancing access and exclusion, 52 internal procedures, review of, 193 historical background, 33 invention disclosure requirements, review open access under, 272 of, 193 International Union for the Protection of New Varieties of Plants (UPOV) IP managers, role of, 192 owned or applied for, 192-193 developing countries and, 55 peripheral individuals, 192 historical background, 33 potential infringement, discovering, plant patents under, 71 193-194 Internet process review, 186-187 clickwrap licenses, 271 questionnaire re, 189-192 global innovation initiative, as, 111-112 categorization, 190-192 Internet Corporation for Assigned Names and comprehensive questionnaires, 190 Numbers (ICANN), 111 confidentiality, 190 "Invent around" strategy, 175-176 counsel, role of, 190 Invisible infrastructure of innovation, 1-3 dissemination of, 190 iPod, 117, 139, 228, 297



402 Index

Irtisen, 26-28, 67, 253 advantages of Israel, piracy in, 313 business resources of licensee, leveraging, iTunes, 117, 139, 228, 277, 297 geographic reach, broadening, 277 J. Craig Venter Institute, 103, 109, 113, 303 market penetration, increasing, 277 Iapan revenue stream, creating, 277-278 Bolar provisions in, 314 underlying ownership interest, patents maintaining, 277 standards for obtaining, 310 antitrust law and, 283-284 volume of, 311 assignment distinguished, 273-274 summary of IP law, 316 bailment, 272 Jefferson, Thomas, 25, 178 "barter" agreements, 271 Jewish law, IP under, 28 benefit sharing agreements, 271 Jobs, Steve biodiversity agreements, 271 Apple Computers and, 117 clickwrap licenses, 271 independent inventor, as, 100 complexity of, 284 innovation by, 117 compulsory licenses (See Compulsory Johns Hopkins University, 298 licenses) Johnson & Johnson, 251 "copyleft" licenses, 42, 112, 276 Joint ownership, 87-90 cross-license agreements, 271 assignment versus licensing, 273 disadvantages of combining different types of IP, 88-89 control, loss of, 278 discrete parts, allocation of rights to, 89 dependency on others for revenue, 278 exclusive rights, lack of, 88 incentive, loss of, 278 overview, 87-88, 95-96 innovation, stopping of, 278 public domain, rights dedicated to, 89 IP rights, risk of loss of, 278 pure joint ownership, 89 recognition, loss of, 278 duration, 280 sharing different types of IP, 89 third party, transfer of rights to, 89 economic terms, 283 transfer of IP rights, 89-90 electromechanical equipment, 305 Joint ventures, 158, 268, 277 end user license agreements (EULAs), 271, 307 Jones, Monty, 107, 108 enforcement, 281 Katz, Ronald, 277 entertainment licenses, 270 Kearns, Robert, 99 exclusivity, 279 Kenya, summary of IP law, 320-321 field of use, 279-280 foreign universities, 298-299 Kilby, Jack, 14 King, Martin Luther, Jr., 301 franchise licenses, 271 governmental agencies, rights of, 272 Knight, Jackson, 173 Knowledge-based innovation, 123 granting clauses, 279 Korea illegal transfers, 272-273 compulsory licenses in, 314 implied licenses, 271 patents, volume of, 311 improvements, 281 summary of IP law, 319 indemnity, 281-283 Kyoto Protocol, 335 joint ventures and, 277 material transfer agreements (MTAs), 272 Lemelson, Jerome, 99, 177 noneconomic terms, 279 Lennon, John, 87, 89 open access licenses, 271, 275-276 Letters patent, 69 operation of law, by, 272 LG Industries, 319 overview, 270, 271 Library of Congress, 269, 273 publishing licenses, 270 recordation of, 273 Licensing of IP rights



| royalties, 283 | overview, 122, 128 |
|---|--|
| shrinkwrap licenses, 271 | Porter on, 125–126 |
| software (See Software) | practical advice, 123–124 |
| sublicenses, 271, 280 | sources of innovation, 122–123 |
| tangible property, effect of transfer of, | technical innovation <i>versus</i> business |
| 271–272 | innovation, 124–125 |
| technology licenses, 270 | Management of IP. See Strategic IP management |
| termination clauses, 280–281 | Market-based valuation |
| territory, 280 | advantages, 218 |
| trademark licenses, 270–271 | disadvantages, 218 |
| transferability, 280 | illustrations, 217–218 |
| warranties, 281–283 | overview, 217 |
| Liens, 270 | Martial, 28 |
| Life sciences. See also Biological materials; | Marvel Comics, 297 |
| Pharmaceuticals | Massachusetts Institute of Technology, 203, 304 |
| strategic IP management, 291–292 | Material transfer agreements (MTAs) 272, 304 |
| Lincoln, Abraham | (See Biological Materials) |
| "fire of genius," 29, 343 | Maverick, Samuel, 180 |
| innovation, on, 343, 344 | Max, Peter, 188 |
| IP, on, 32, 344 | McCartney, Paul, 87, 89 |
| patents, on, 28, 29, 31, 32, 343 | McDonald's, 157, 217, 294 |
| Linux | Mediation, comparative law re, 313 |
| access to software, 140, 231 | Medicine. See Pharmaceuticals |
| open source software and, 112, 157, 181, 182 | Merck, 140, 328 |
| trade secrets, 293 | Mergers, 268–269 |
| Lipitor, 117, 292 | Merial, 109 |
| Locke, John, 38 | Mexico |
| Lopez de Arriortua, Jose Ignacio, 152, 259 | examples of IP law, 320 |
| Loratidine, 329 (See Claritin) | MGM, 39 |
| Madrid Protocol | Michelangelo, 18 |
| historical background, 32 | Mickey Mouse, 79 Microsoft |
| trademarks under, 245, 316 | |
| Major League Baseball, 208 | access to software, 231 copyright licenses, 112 |
| Makerere University, 102 | enforcement of IP rights, 313 |
| Management of innovation, 122–128 | infringement, damages for, 315 |
| Christenson on, 125 | innovation, impact of, 11 |
| cluster theory of competition and, 125–126 | joint ventures, 158 |
| corporations, in, 126–127 | Office suite, 158 |
| "creative construction" concept and, 124 | open peer review, 113 |
| creative destruction concept and, 122, 125 | open source software and, 182 |
| Davila on, 124–125 | trademarks, 293 |
| Drucker on, 122–124 | Middle Ages, IP during, 28 |
| government planning, role of, 124 | Minimalist strategy, 165–166 |
| intellectual asset management (IAM), | Mission statements, 139 |
| 126–127 | Monetizing of IP assets, 223 |
| intellectual capital management (ICM), | Monopolies |
| 126–127 | creation of as criticism of IP, 41 |
| IP management, importance of, 124, 125 | IP rights contrasted, 254–255 |
| knowledge-based innovation, 123 | Monsanto, 80 |
| new and old ventures, separating, 124 | Montagnier, Luc, 14 |
| outside of corporations, 127–128 | Moral rights, 38, 39, 275 |
| | |



| "Move quickly and hold on" stratogy 190 | converights 202 202 |
|--|---|
| "Move quickly and hold on" strategy, 180 Mullis, Kary, 18 | copyrights, 202–203 overview, 202 |
| Multinational research consortia, 109–111 | patents, 203 |
| benefits of, 111 | trademarks, 203 |
| competition, effect of, 109–110 | trade secrets, 202 |
| examples of, 109 | funding of, 103–104 |
| product development partnership model, | innovation and, 103–104 |
| 110–111 | internal assets valuation in, 188 |
| Music | IP management, 104 |
| access to innovation, 231 | overview, 103 |
| copyrights in, 296 | partnering practices, 158 |
| digital, 296–297 | product development partnerships, 299 |
| file reproduction technology in, 56, 296–297 | protection of innovation in, 239–240 |
| public domain and, 47 | publication by, 297, 298 |
| symphony orchestras | purposes of, 104 |
| copyrights and, 300–301 | strategic IP management, 297 |
| importance of IP rights to, 300 | trade secrets and, 297 |
| trademarks in, 297 | types of institutions, 103 |
| "Mutual assured destruction" strategy, 171–172 | valuation of IP assets in, 208–209 |
| Myhrvold, Nathan, 118, 136 | Norway, compulsory licenses and, 314 |
| MySpace, 113 | Novartis, 328 |
| Myopace, 113 | Noyce, Robert, 14 |
| Nanotechnology, 20–21 | NTP (See Blackberry) |
| National Cancer Institute, 178, 329 | Nutrasweet, 80 |
| National Center for Biotechnology Information, | rvatiusweet, oo |
| 208 | Ocean Tomo, 219, 269 |
| National Institutes of Health | Olympics (Beijing), 205 |
| access to research tools, 222 | Open access |
| databases, 182 | ABCD model of transfer of IP rights, 181, |
| development of pharmaceuticals by, 329 | 182 |
| licensing of pharmaceuticals by, 178, 209 | balancing access and exclusion, 52 |
| patent portfolio, 298 | biotechnology and, 336 |
| publication by, 208 | expanding access by assertion of IP rights, 183 |
| research by, 103 | growth of, 182 |
| sunk costs, 212 | licenses, 271, 275–276 |
| Natural law concepts of IP, 24, 38–39 | Linux model, 181 |
| NCAA, 208 | overview, 182 |
| Nebhepetra Mentuhotep, 26, 253 | plants, 272 |
| Need for shared framework, 3–4 | public domain distinguished, 113, 181–182 |
| Negotiation. See Transfer of IP rights | publishing, in, 182 |
| Net present value, calculation of, 214, 216 | underlying IP rights as basis of, 181 |
| New Rice for Africa (NERICA), 108 | Open innovation communities, 112–113 |
| Newton, Isaac, 15 | genetic sequences and, 113 |
| New York Intellectual Property Law Association, | media and, 112–113 |
| 254 | open peer review, 113 |
| New York Times, 275 | open source software, 112 |
| NeXT Computers, 117 | public domain distinguished, 113 |
| Nike, 170 | Wikipedia as, 112 |
| Noncompetition covenants, 150, 196 | Open source software |
| Nonprofit organizations | innovation community model, 112 |
| advocacy and, 103 | Linux (See Linux) |
| external environment evaluation | partnering practices, 157 |



Index 405

Organization for Economic Cooperation and biotechnology, disclosure requirements, 336-337 Development, promotion of innovation by, 34 broader claims, pursuing, 252 Ownership of IP rights comparative law corporate ownership distinguished, standards for obtaining, 310-311 267-268 volume of, 311 different types of IP contrasted, 267 conversion to different type of IP, 79-81, 175 joint ownership (See Joint ownership) counting, valuation by, 223 public domain and, 267 "designing around," 234 tangible property ownership distinguished, design patents, 71 electromechanical equipment, in, 305 terminology of ownership, 267 electronics, in, 293 Oxford English Dictionary, 22 enforcement of, 260-261 entertainment industry, in, 295 Pan American World Airways, 251 environmental technology, in, 335 Panti, Don Elijio, 108 exceptions, 246 Parallel imports (gray market), 318 expiration, 70 Paris Convention external environment evaluation (See applications under, 252 External environment evaluation) fair use of, 235-236 historical background, 32 patent protection under, 247 fees, 69 Partnering practices, 156–158 foreign applications, 252-253 affiliates, 157 foreign universities and, 298-299 franchises, 157-158 homeland security technology, expedited holding companies, 157 process for, 331-332 joint ventures, 158 infringement nonprofit organizations, 158 damages, 222 defenses, 70 open source software, 157 partnerships, 158 remedies, 70 service contracts, significance of, 156-157 interactions with other types of IP, 78-79 strategic alliances, 158 internal asset evaluation re (See Internal asset Patent and Trademark Office (UK), 321 evaluation) Patent and Trademark Office (US) invention disclosure requirements, 246-247 assignments, recordation of, 269, 270 inventiveness element, 71 disclosures to, 199 letters patent, 69 independent inventors and, 99 life sciences, in, 292 licenses, recordation of, 270 loss of rights, 70 open peer review process, 113 non-strategy model of IP management, effect public databases, 223 of, 133-134 obtaining, 69-70 streamlining of processes, 315 Patent Cooperation Treaty (PCT) overview, 69, 83 applications under, 247, 252, 311 ownership of, 267 historical background, 33 parallel protection, 247 patent protection under, 247 Paris Convention, protection under, 247 Sierra Leone and, 320 patent "jiu jitsu," 175 WIPO administration of, 32 patent pending, 69 Patent License Exchange, 219 patent thickets, 169 Patents, 69-71 patent traps, 174 abandonment, 253 patent "trolls," 155, 171-172, 325 applications for, 69-70, 252 perfecting applications, 253 balancing access and exclusion in, 45, 51 pharmaceuticals, in, 292 biological materials, in, 79, 292, 303-304 plants, in, 71



| Patents (cont.) | innovation communities in, 101 |
|--|--|
| portfolio management, 252–253 | trademarks, 292 |
| protection of innovation (See Protection of | Pfizer, Charles, 100 |
| innovation) | Pharmaceuticals |
| provisional applications, 247 | access to innovation, 231–232 |
| "pruning" of, 252 | AIDS medicines |
| publication of, 70 | Brazil, in, 128 |
| reexamination requests, 178 | conversion to different type of IP, 79 |
| right to exclude, 70–71 | public domain and, 47 |
| software, in, 293, 306 | unnamed co-inventors and, 178 |
| strategic IP management, patent-specific | antitrust law and, 284 |
| strategies, 172 | blocking rights in, 91 |
| "submarine" patents, 176–177 | copyrights and, 292 |
| sunk cost-based valuation, 212 | developing countries and, 55 |
| table, 70 | CIPIH report, 55–56 |
| telecommunications, in, 293 | generic drugs versus branded drugs |
| trade secrets, relationship with, 69 | (See Generic drugs versus branded |
| transfer of IP rights, 274–275 | drugs) |
| TRIPS Agreement | India, pharmaceutical industry in, 40, |
| consistency of, 310 | 317–318 |
| fair use under, 236 | IP thicket strategy, 169 |
| protection under, 246 | patents and, 292 |
| uncited prior art, 178 | product development partnerships, 299 |
| universities and, 297–298 | strategic IP management, 291–292 |
| unnamed co-inventors, 178 | trademarks and, 292–293 |
| utility patents, 70 | trade secrets and, 292 |
| Venetian Patent Decree of 1474 (See Venetian | trends in IP system re, 56 |
| Patent Decree of 1474) | PIIPA. See Public Interest Intellectual Property |
| visionary model of IP management, effect of, | Advisors |
| 136 | Piracy |
| Paxil, 329 | comparative law re, 313 |
| PCT. See Patent Cooperation Treaty | copyrighted material, of, 73 |
| Penicillin, 19, 123 | Piracy of copyrighted material, 73 |
| PepsiCo, 273, 317 | Pixar Studios, 117 |
| Personnel practices 149–152 (See also | Pizza Hut, 157 |
| Employment) | Plants |
| authorship, concept of, 151 | access to innovation, 231 |
| confidentiality agreements, 150 | International Treaty on Plant Genetic |
| employment contracts, 150 | Resources for Food and Agriculture (See |
| internal <i>versus</i> external IP rights, 150 | International Treaty on Plant Genetic |
| invention disclosure requirements, | Resources for Food and Agriculture) |
| 151 | open access to, 272 |
| noncompetition covenants, 150 | patents in, 71 |
| overview, 149–150, 162 | UPOV (See International Union for the |
| recruitment, during, 150–151 | Protection of New Varieties of Plants) |
| review of, 152 | Polaroid, 119, 208, 238, 261, 315 |
| termination, during, 152 | Policing. See Enforcement of IP rights |
| Petrash, Gordon, 126 | Policy for IP management, 148–149 |
| Pfizer | communication of, 149 |
| challenging patents of, 117, 292, 319 | overview, 162 |
| generic drugs <i>versus</i> branded drugs, 328 | policy statements, 148–149 |
| | |



| review of, 149 | IP assets, as, 242–244 |
|--|--|
| triggering events, 149 | nonprofit organizations, in, 239–240 |
| Political parties and innovation, 104–105 | overview, 239, 262 |
| Porter, Michael, 106, 125–126, 128 | patents |
| Portfolio management | applications, 247 |
| affirmative steps to protect IP rights, 153 | costs, 247–248 |
| categorization of assets, 248 | invention disclosure requirements, 246-247 |
| common elements, 153 | overview, 246 |
| communication, channels of, 153 | parallel protection, 247 |
| copyrights, 250–251 | provisional applications, 247 |
| evaluation, 153 | timing considerations, 248 |
| forestry analogy, 248 | trademarks |
| innovation triage in, 248–249 | costs, 246 |
| monitoring, 153 | high level of investment, 245 |
| overview, 152-153, 162, 248, 262 | low level of investment, 245-246 |
| patents, 252–253 | overview, 245 |
| regularity, importance of, 248 | procedural requirements, 245 |
| strategic IP management, in, 152–153 | trade secrets |
| trademarks, 251–252 | high level of investment, 244 |
| trade secrets, 250 | overview, 244 |
| Posey, Darrell, 52 | self-help, 244 |
| Precautionary principle, 20 | Protection of IP rights. See Enforcement of IP |
| Princeton University, 102 | rights |
| Printers, 284 | Proudhon, Pierre-Joseph, 43 |
| Prior art, 178 | PTO. See Patent and Trademark Office (US) |
| Privity, 93 | Public agencies. See Governmental agencies |
| Prizes as alternative to IP rights, 58–59, 343 | Public disclosure |
| Procurement practices, 153–156 | lack of, historical impact of, 28 |
| criticism of IP, overcoming of, | promotion of, 39 |
| 155–156 | Public domain. See also "Accessible domain" |
| freedom to operate, ensuring, | AIDS medicines and, 47 |
| 154–155 | consumers, attitude of, 46–47 |
| genetic sequences, 154–155 | copyrights |
| infringement claims, effect of, 155 | dedication of, 250–251 |
| licensing of assets, 154 | entry of copyrighted material into, 72 |
| overview, 153–154, 162 | dynamic relationship with IP, 46 |
| ownership of assets, 154 | false dichotomy with IP, 46, 47 |
| public domain, assets in, 154 | innovation cycle, effect of, 46 |
| risks, 154 | IP contrasted, 45–46 |
| what may be procured, 154 | joint ownership rights dedicated to, 89 |
| Product development partnerships (PDPs), | keeping innovation out of as criticism of IP, 40 |
| 110–111, 299 | limitations of, 45–47 |
| Protection of innovation with IP rights | multiple public domains, concept of, 46 |
| comparative law, 309 | music and, 47 |
| copyrights | open access distinguished, 181–182 |
| high level of investment, 245 | open innovation communities distinguished, |
| low level of investment, 245 | 113 |
| notice, importance of, 244–245 | ownership of IP rights and, 267 |
| overview, 244 | trademarks, entry of, 75–76 |
| decision-making process, 239 | trade secrets, entry of, 68–69 |
| innovation triage (See Innovation triage) | transfer of IP rights, inapplicability to, 86 |
| iiiiovation triage (see iiiiovation triage) | transfer of ir rights, mappincability to, 86 |



408 Index

Public Interest Intellectual Property Advisors Reebok, 170 Regional innovation communities, 106-107 developing countries, delivery of IP services Relief from royalty model, valuation by, 217 in, 57, 104, 122, 127, 204-205 Religious organizations formation of, 42 copyrights and, 106 Ibis Reproductive Health and, 205 innovation and, 105-106 International Alpaca Association and, 205 limitations of IP principles, 105 Kenyan free trade coalition, assisting, 321 morality, relevance of, 106 Light Years IP, and, 205 symbols and, 105-106 surveys by, 109 trademarks and, 106 Public Library of Science, 182 Research in Motion (RIM) See Blackberry Public performances Research organizations multinational research consortia (See comedy, copyrights and, 301 dance, copyrights and, 301 Multinational research consortia) public speeches, copyrights and, 301 nonprofit organizations (See Nonprofit strategic IP management, 299 organizations) symphony orchestras Research tools, 376-378 copyrights and, 300-301 Rivette, Kevin, 142 importance of IP rights to, 300 Roche, 208, 217, 222, 238, 319 theater Rome, IP in, 28 copyrights and, 299-300 Royalties, 283 importance of IP rights to, 300 RoyaltyPharma, 189, 215, 221, 223, 324 trademarks and, 300 Publishing licenses, 270 criminal offenses in, 314 Pullman, David, 296 patents, volume of, 311 Pullman Group, 324 piracy in, 313 Purchasing. See Procurement practices summary of IP law, 317 Rutan, Bert, 58 Qualcomm, 208, 222 San Diego, University of California at, 113 Raghavan, Vijaya, 117 Sandoz, 328 Rainforest Action Network, 335 Santayana, George, 26 Rajiv Gandhi School of Intellectual Property Saudi Arabia, role of negotiation in, 312 Law, 26 Scaled Composites, 58 Rambus, 174-175 Schawlow, Arthur, 176 Ranbaxy, 117, 292 Schering-Plough, 175, 329 Rationale for IP, 37-40 Schumpeter, Joseph fruits of creativity, enjoyment of, 38 creative destruction theory, 11, 12, 19, 122 incentive for creativity, 38 dynamic innovation theory, 41 industrial policy, implementation of, 40 Science Commons Project, 276 investment in innovation, facilitation of, Scotch Whisky Association, 318 39 - 40Screening of innovations, 227-228 moral rights, 38-39 Securitization of IP rights natural rights, 38-39 advantages of, 323 overview, 36-37, 59 criticism of, 325 public disclosure, promotion of, 39 examples of, 324 reward for creativity, 38 growth in, 324 transfer of innovation, facilitation of, 39 innovation, impact on, 325 Real Options Theory, 219-220 market-driven nature of, 324-325 Recording industry. See Music obstacles to, 324 Recording Industry Association of America, 47 overview, 322-323 Red Hat, 157 patent "trolls" compared, 325



Index 409

Special Purpose Vehicles (SPVs), 323 Special Purpose Vehicles (SPVs), 323 Spiderman, 297 table, 323 Security interests, 270 Starbucks, 157 State agencies. See Governmental agencies Sen, Amartya, 342 Service contracts, 156-157 State Department, 332 Shakespeare, William, 19, 48, 229, 234, 300 Statute of Monopolies, 30 Shreeve, James, 109 Stiglitz, Joseph, 41 Stockholm Convention on Persistent Organic Shrinkwrap licenses, 271 Shuster, Joe, 297 Pollutants, 334 Siegel, Jerry, 297 Stolichnaya, 317 Sierra Leone, summary of IP law, 320 Strategic alliances, 158 Strategic IP management Sigma-Aldrich, 292 "Aleppo Citadel" strategy, 170 Singapore, volume of patents in Singh, Malvinder, 117 "anti-invent around" strategy, 176 Small businesses bargaining chip strategy, 170-171 innovation and, 100-101 "blanket" strategy, 173 strategic IP management, 289-290 branding, 179-180 Small groups and innovation, See Individuals "burning stick" strategy (See "Burning stick" and small groups and information strategy) Smallpox, 332 capital, consideration of, 144 Smith-Kline Beecham, 263 communication of strategy, importance of, Smithsonian Institution, 103 164 - 165Snap Trak, 208, 222 comparative law, 308-309 Social value of IP assets, 223-224 competitive environment, studying, 144 Social welfare and innovation, 342 benchmarking, 144 Software competitive intelligence and, 144 confidentiality agreements and, 305-306 issues to assess, 144 copyrights in, 293, 306 conversion from patent to trademark, 175 different types of IP involved, 79 copyright-specific strategies, 181 licensing of IP rights, 307 cost control model, 134-135 access to innovation, 231 cost management (See Cost management) defensive model, 134 agreements, 85 end user license agreements (EULAs), 271, development of plan, 144-145 access to IP assets of others, 145 internal asset evaluation, issues re, 195 copyrights and, 145 open source software patents and, 145 innovation community model, 112 protecting own IP assets, 145 Linux (See Linux) "do-nothing" organizations, converting, 165 partnering practices, 157 enforcement (See Enforcement of IP rights) "fence" strategy, 173 patents in, 293, 306 "first one's free" strategy, 172 strategic IP management, 293 trademarks in, 293, 306-307 "flood" strategy, 173 trade secrets in, 293, 305 forest strategy, 169-170 Sony, 293 forming strategy, 139 Sophocles, 28 goals (See Goals of IP management) Sources of innovation, 122-123 growth stages, differences in South Africa large businesses, 290 compulsory licenses in, 314 multinational corporations, 290 patents, standards for obtaining, 310, 311 small businesses, 289-290 summary of IP law, 320 start-up companies, 289 South Pacific, University of, 263 table, 290 Spain, Bolar provisions in, 314 "homesteading" strategy, 172-173



410 Index

Strategic IP management (cont.) procurement practices (See Procurement human resources, assessing, 141-142 practices) globalization, impact of, 141 profit center model, 135 screening of innovations, 227-228 identifying creative personnel, 141 legal advice, 141 simplicity of strategy, importance of, 164-165, "hurdle" strategy, 174 strategic reassessment (See Strategic implementation of plan, 145-146, 226-227 industries or sectors, differences in (See also reassessment) "submarine" patents, 176-177 specific industry or sector) overview, 291 "suit of armor and shield" strategy, table, 291 167-168 integrated model, 135 supermonopoly, 174-175 "invent around" strategy, 175-176 supply chain management, 153-154 inventory, consideration of, 144 sword versus shield model, 171 IP practices, assessing, 143-144 technologies, differences in (See also specific IP resources, assessing, 142-143 technology) existing assets, 142 overview, 301-302 goodwill, 142 table, 302 valuation, 142-143 thicket strategy, 168-169 Level Five organizations, 135-136 tight budget strategy, 166 "toll gate" strategy, 173-174 Level Four organizations, 135 Level One organizations, 134 tools for, 147-148, 162 levels of, 131-132 trademark clusters, 180-181 Level Three organizations, 135 trademark-specific strategies, 179-181 Level Two organizations, 134-135 trade secrets Level Zero organizations, 132-134 IP practices as, 143 minimalist strategy, 165-166 trade secret-specific strategies, 178-179 "move quickly and hold on" strategy, trade secrets versus patents, 179 treble damages, avoiding, 177 "Mutual assured destruction" strategy, uncited prior art, 178 171-172 unnamed co-inventors, 178 non-policy parody, 361-364 visionary model, 135-136 non-strategy model, 132-134 copyrights, effect on, 135-136 confidentiality and, 133 patents, effect on, 136 "wall" strategy, 174 consequences of, 132–133 copyrights, effect on, 133 Strategic reassessment, 161-162 patents, effect on, 133-134 financial valuation, 161 reasons for, 132 noneconomic valuation, 161 trademarks, effect on, 134 simplicity of plan, importance of, options, 163, 164-165, 182-183 161 - 162overview, 131, 136-139, 146, 307 Sublicenses, 271, 280 partnering practices (See Partnering "Submarine" patents, 176-177 "Suit of armor and shield" strategy, 167-168 practices) patent "jiu jitsu," 175 Sullivan, Patrick, 23, 126 patent-specific strategies, 172 Sunk cost-based valuation. See Cost-based patent traps, 174 valuation personnel practices (See Personnel practices) Superman, 79, 297 policing (See Enforcement of IP rights) Supermonopoly, 174–175 policy for IP management (See Policy for IP Supply chain management, 153-154 management) Swanson, Robert, 117 portfolio management (See Portfolio Swift, Jonathan, 208 Sword versus shield model, 171 management)



| C | |
|---|---|
| Symbol Technologies, 177 Symphony orchestras | comparative law re standards for obtaining, 311–312 |
| copyrights and, 300–301 | consumer products and services, in, |
| importance of IP rights to, 300 | 294 |
| importance of ir rights to, 500 | conversion to different type of IP, 79–81 |
| Taiwan | developing countries and, 108 |
| compulsory licenses in, 314 | dilution, 75 |
| summary of IP law, 319 | distinctiveness, concept of, 74–75 |
| Tamiflu, 331 | duration, 75 |
| Tangible property | electromechanical equipment, in, 305 |
| copyrights separate from, 275 | electronics, in, 293 |
| | enforcement of, 75, 260 |
| licensing of IP rights, effect of transfer on, 271–272 | entertainment industry, in, 297 |
| ownership of IP rights distinguished from | environmental technology, in, 335 |
| ownership of tangible property, 268 | EU, community trademarks in, 245, 316 |
| | external environment evaluation (See |
| transfer of IP rights, tangible property analogy, 84 | External environment evaluation) |
| Taxol, 329 | fair use of, 235 |
| Teams. <i>See</i> Innovation teams | , |
| Technical manuals, 79 | infringement, damages, 222 interactions with other types of IP, 78–79 |
| | internal asset evaluation re (See Internal asset |
| Technology licenses, 270 Telecommunications | evaluation) |
| copyrights in, 293 | licenses, 270–271 |
| | life sciences, in, 292–293 |
| patents in, 293 strategic IP management, 293 | |
| trademarks in, 293 | loss of rights, 75 |
| trade secrets in, 293 | Madrid Protocol, under, 245, 316 maintenance, 251 |
| Termination clauses, 280–281 | • |
| · · | music, in, 297 |
| Terrorism. See Homeland security | non-strategy model of IP management, effect |
| technology | of, 134 |
| Teva, 329 | obtaining, 73–74 |
| Texas Instruments, 293 | overview, 73, 83 |
| Thailand, compulsory licenses in, 314 | ownership of, 267 |
| | pharmaceuticals, in, 292–293 |
| Theater | portfolio management, 251–252 |
| copyrights and, 299–300 | protection of innovation |
| importance of IP rights to, 300 | costs, 246 |
| trademarks and, 300 | high level of investment, 245 low level of investment, 245–246 |
| Thicket strategy, 168–169 | |
| Third-party IP rights, 237 Thompson, Tommy, 329 | procedural requirements, 245 |
| 2 | public domain, entry into, 75–76 |
| Thoreau, Henry David, 227 | religious organizations and, 106 |
| Tight budget strategy, 166 | renewal, 251 |
| Time Magazine, 113 "Toll gate" strategy, 173–174 | software, in, 293, 306–307 |
| Townes, Charles, 14, 176 | strategic IP management, trademark-specific |
| | strategies, 179–181 |
| Toyota, 174, 227 | sunk cost-based valuation, 212 |
| Trademarks, 73–76 | table, 74 telecommunications, in, 293 |
| abandonment, 251–252 | |
| balancing access and exclusion in, 45, 52 | theater and, 300 |
| biological materials, in, 292–293, 304 | trademark clusters, 180–181 |
| Diological illaterials, iil, 292–293, 304 | transfer of IP rights, 276 |



412 Index

Trademarks (cont.) fair use under, 236 TRIPS Agreement, protection under, 245 protection under, 244 universities and, 298, 299 universities and, 297 Trade secrets, 67-69 violations, 67-68 balancing access and exclusion in, 45, 52 Traditional knowledge, 52, 77-78, 318, 336, 337 biological materials, in, 79, 292, 302 Traffix Devices, 175 confidentiality agreements, breach of, 259 Transfer of IP rights ABCD model (See ABCD model of transfer of consumer products and services, in, 294-295 conversion to different type of IP, 79-81 IP rights) copyrights, relationship with, 69 acquisition of IP rights (See Acquisition of IP definition of, 67 rights) electronics, in, 293 assignment (See Assignment of IP rights) enforcement of, 68, 257-259 basic principles, 264 collaborators, 89-90 entertainment industry, in, 295 environmental technology, in, 335 complexity of, 84 external environment evaluation (See consideration, 264-265 External environment evaluation) contracts, 87 fair use of, 236 copyrights, 275-276 genetic sequences, in, 302-303 consulting agreements, 275 homeland security technology, in, 332 "copyleft" licenses, 276 open access licenses, 275-276 human genome and, 69 infringement, damages, 222 overview, 275 interactions with other types of IP, 78-79 tangible property, separation from, 275 internal asset evaluation re (See Internal asset full transfer, 87 evaluation) individual transfer of IP rights, 86 life sciences, in, 292 infringement (See Infringement) loss of status, 68-69 joint ownership, 89-90 nonprofit organizations and, 297 legal language, 265 overview, 67, 83 licensing (See Licensing of IP rights) ownership of, 267 management, importance of, 84 patents, relationship with, 69 mutual assent, 265 pharmaceuticals, in, 292 negotiating considerations portfolio management, 250 comparative law re, 312 protection of, 67 consensus building, 285 protection of innovation flexibility, 285 goals of, 285 high level of investment, 244 human factor, 284-285 low protection, 243 self-help, 244 noneconomic terms, 285 public domain, entry into, 68-69 overview, 86-87 secrecy, concept of, 68 research, 285 "self-help," 67 strategic planning, 285 software, in, 293, 305 overview, 84, 95-96, 263, 285-286 strategic IP management ownership of IP rights (See Ownership of IP IP practices as, 143 rights) partial transfer, 87 trade secret-specific strategies, 178-179 trade secrets versus patents, 179 patents, 274-275 sunk cost-based valuation, 212 property that may be transferred, 85-86 table, 67 public domain, inapplicability of, 86 telecommunications, in, 293 rights that may be transferred, 85-86 theft of, 152, 257-259 scope of license, determining, 86 transfer of IP rights, 274 specialists, role of, 284 TRIPS Agreement tangible property analogy, 84



| trademarks, 276 | fair use of, 236 |
|--|--|
| trade secrets, 274 | protection of, 246 |
| types of transfers, 268 | plant patents under, 71 |
| writing, importance of, 265 | protection of IP rights generally, 244 |
| Treble damages, avoiding, 177 | public order or morality, inventions contrary |
| Tree metaphor, See Innovation tree metaphor | to, 303 |
| Trends in IP system, 56–59 | tensions under, 53 |
| "accessible domain," enlargement of, 57 | trademark protection under, 245 |
| continued importance of IP, 59 | trade secrets |
| "creative construction," 57–58 | fair use of, 236 |
| file reproduction technology, 56 | protection of, 244 |
| future scenarios, 338 | widespread adoption of, 53 |
| business, 339 | Tucker Act, 332 |
| governments, 339 | Turner, Ted, 38 |
| political groups, 340 | 25% rule in valuation, 221 |
| technologies, 340 | Tylenol, 124 |
| grants and prizes as alternative to IP rights, | Types of IP |
| 58–59 | biological materials, 77 |
| law, limitations of, 58 | conversion to different type, 79–81 |
| new groups, involvement of, 56 | copyrights (See Copyrights) |
| pharmaceuticals, in, 56 | databases, 77 |
| possible outcomes | domain names, 76 |
| expansion of IP protection, 57 | employee rights, 77 |
| rollback of IP protection, 57 | geographical indications, 76–77 |
| social goals, promotion of, 57 | interactions between, 78–79 |
| status quo, preservation of, 56–57 | overview, 76, 82–83 |
| predictions, 58 | patents (See Patents) |
| Triage | trademarks (See Trademarks) |
| enforcement triage (See Enforcement triage) | trade secrets (See Trade secrets) |
| innovation triage (See Innovation triage) | traditional knowledge, 77–78 |
| TRIPS Agreement | |
| adoption of, 25 | Uniform Domain Name Dispute Resolution |
| balancing access and exclusion, 52 | Policy, 313 |
| biological materials under, 303 | Union Oil Company of California, 174 |
| compulsory licenses under, 314, 330 | United International Bureau for the Protection |
| convergence of national laws resulting from, | of Intellectual Property, 22, 32 |
| 308, 309 | United Nations, use of copyrights by, 202 |
| copyright protection under, 244 | United States |
| definition of IP, 23 | Bolar provisions in, 314 |
| developing countries, lack of full | Commerce Department, 332 |
| implementation in, 309 | Constitution |
| drug patents under, 330 | Eleventh Amendment, 332 |
| Eurocentric nature of, 53 | IP under, 24–25 |
| excerpts, 346–360 | environmental regulation in, 333 |
| geographical indications under, 76 | Federal Trade Commission, 174, 284, 329 |
| historical background, 33 | Homeland Security Act of, 2002, 331 |
| India, laws adopted in compliance with, 117 | patents |
| integrated circuits under, 305 | standards for obtaining, 310 volume of, 311 |
| involvement of new groups under, 56 | • |
| laws adopted in compliance with, 43, 65–66 | summary of IP law, 315 |
| patents consistency re, 310 | Trade Representative, 313 Universal Declaration of Human Rights, 55, 337 |
| consistency ie, 510 | Omversar Decraration of Human Rights, 55, 537 |



| Universities | purposes of, 210 |
|--|--|
| academic freedom in, 298 | Real Options Theory, 219–220 |
| assignment of IP rights and, 269–270 | relief from royalty model, 217 |
| Bayh-Dole Act, impact of, 34, 103, 297 | replacement cost-based valuation, 213–214 |
| copyrights and, 299 | rules of thumb, 220–221 |
| foreign universities, 298–299 | social value, 223–224 |
| innovation and, 102–103 | statistics re, 208 |
| internal assets valuation in, 189 | strategic IP management, as part of, 142–143 |
| patents and, 297–298 | sunk cost-based valuation (See Cost-based |
| publication by, 297, 298 | valuation) |
| strategic IP management, 297 | table, 211 |
| trademarks and, 298, 299 | threshold questions, 210 |
| trade secrets and, 297 | 25% rule, 221 |
| valuation of IP assets, 222–223 | type of IP, relevance of, 210 |
| UPOV. See International Union for the | universities, 222–223 |
| Protection of New Varieties of Plants | Venetian Patent Decree of 1474, 29–31 |
| U.S. Pharmacopeia, 292 | enactment of, 37 |
| Utility patents, 70 | enforcement under, 253 |
| | influence of, 31 |
| Valuation of IP assets | infringement under, 29 |
| auctioning of assets, 219 | mechanical devices, applicability to, 305 |
| Black-Scholes option pricing formula, | overview, 29 |
| 219–220 | patents issued under, 29 |
| cash value model (See Income-based | provisions of, 30–31 |
| valuation) | text of, 31 |
| commercial ventures, in, 208 | Venezuela, summary of IP law, 320 |
| comparables, by (See Market-based | Venter, Craig, 14, 16, 110, 118, 303 |
| valuation) | Viagra, 319, 328 |
| cost-based valuation (See Cost-based | Vioxx, 328 |
| valuation) | Volkswagen, 152, 259 |
| differing approaches, 209–210 | Voltaire, 208, 333 |
| discounted cash flow, calculation of, 214, 216 | |
| driving force of IP system, as measure of, 224 | "Wall" strategy, 174 |
| established royalty rates, use of, 220 | Wal-Mart, 294 |
| fair market valuation (See Market-based | Walt Disney Company, 79, 100, 117, 295 |
| valuation) | Warranties, 281–283 |
| 5% rule, 220–221 | Watson, James, 303 |
| Georgia-Pacific factors, 218–219 | Watt, James, 14 |
| governmental agencies, 222–223 | White, Tony, 118 |
| hybrid methods, 218–220 | Wikipedia |
| hypothetical royalty negotiations, 218–219 | "copyleft" licenses, 42, 112 |
| importance of, 207–210 | copyrights and, 229 |
| income-based valuation (<i>See</i> Income-based | editing of, 49 |
| valuation) | GNU Free Documentation License, 276 |
| licensing situations, 222 | internal IP assets, evaluation of, 188–189 |
| methods of, 210 | open access and, 43, 140, 182 |
| monetizing of assets, 223 | public domain and, 45 |
| net present value, calculation of, 214, 216 | Wilson, E.O., 17 |
| nonprofit organizations, in, 208–209 | Woods, Tiger, 188 |
| overview, 185, 207–208, 224–225 | World Health Organization (WHO) |
| ownership of asset, relevance of, 210 | copyrights, use of, 202 |
| patent counting, 223 | disease, initiatives to fight, 111 |
| r 00 diriming, ==0 | |



Index 415

pharmaceuticals and developing countries, report on, 55–56 World Intellectual Property Organization (WIPO) Arbitration and Mediation Center,

Arbitration and Mediation Center

copyrights, use of, 202–203 Copyright Treaty, 296 definition of IP, 22–23 domain names, arbitration system re,

historical background, 32 involvement of new groups, 56 patents, statistics on, 311 piracy, report on, 313 rational for IP rights, 36 record searches, 199 traditional knowledge, protection of, 78 Uniform Domain Name Dispute Resolution Policy, 313

World Trade Organization (WTO)
Doha Declaration, 314
historical background, 33
TRIPS Agreement (*See* TRIPS Agreement)

Wozniak, Steven, 151, 152

W.R. Grace, 234 Wright brothers, 14

Xerox, 75

Yale University, 324 YouTube, 113, 136

Zostrix, 234